Asceneuron receives regulatory approval for phase 1 healthy volunteer study of oral tau inhibitor

10th April 2017 Uncategorised 0

B3C newswire

More: Asceneuron receives regulatory approval for phase 1 healthy volunteer study of oral tau inhibitor
Source: MDlinx